The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens.
BACKGROUND
There has been relatively little written on the diagnosis and reporting of adenocarcinoma of the prostate diagnosed in core needle biopsy specimens.


METHODS
This article reviews issues concerning diagnosing, grading, and quantification of prostate carcinoma in core needle biopsy specimens.


RESULTS
The diagnosis of prostate carcinoma in core needle biopsy specimens is discussed, including the relative frequency and utility of various architecture, cytologic, and ancillary features. Grading of prostate carcinoma in core needle biopsy specimens is evaluated along with the relationship of core needle biopsy grade to corresponding radical prostatectomy grade. The relationship between the extent of carcinoma in core needle biopsy specimens to extent of tumor in the radical prostatectomy is summarized. Finally, this article summarizes articles supporting the use of high molecular weight cytokeratin in the diagnosis of adenocarcinoma of the prostate in core needle biopsy specimens.


CONCLUSIONS
Pathologists are not only called upon to diagnose limited cancer in core needle biopsy specimens, but also to quantify and grade these cancers accurately. Issues relating to this pathologic evaluation are critical for physicians treating men with adenocarcinoma of the prostate.
Epstein
J I
JI
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D014408:Biomarkers, Tumor / Q000032:analysis; D001707:Biopsy, Needle; D002277:Carcinoma / Q000473:pathology / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008297:Male; D008970:Molecular Weight; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery
D014408:Biomarkers, Tumor; D007633:Keratins